Aug 5, 2015 1:30 pm EDT Eyegate Pharmaceuticals Announces Closing of Public Offering of Common Stock and Warrants
Jul 30, 2015 6:08 pm EDT EyeGate Pharmaceuticals Announces Pricing of $10,000,000 Public Offering of Common Stock and Warrants
Jul 24, 2015 8:30 am EDT EyeGate Pharma Receives USPTO Notice of Allowance for Proprietary Dexamethasone Phosphate Formulation
Jul 14, 2015 8:30 am EDT EyeGate Pharma Treats First Patient in Phase 1b / 2a Trial of EGP-437 in Macular Edema
Jul 10, 2015 8:30 am EDT EyeGate Signs Licensing Agreement with Valeant Pharmaceuticals for EGP-437 Combination Product in Uveitis
May 4, 2015 8:30 am EDT EyeGate Pharma Receives Positive Guidance From FDA on NDA Filing Requirements of EGP-437 for the Treatment of Anterior Uveitis
Mar 2, 2015 8:30 am EST Eyegate Pharmaceuticals Names Michael B. Raizman, MD, Consulting Chief Medical Officer